Johnson & Johnson announced Wednesday that a clinical trial showed a second injection of a COVID-19 vaccine produced a nine times higher antibody response than the US pharmaceutical company’s first dose.
In a news release, the company said it had conducted two Phase 1/2a studies on individuals who were previously vaccinated with a single injection. The study’s preliminary data show booster injection doses produce a “rapid and potent spike in binding antibody. The booster vaccine binds to and neutralizes the invading virus.”
–
–
–
The company described the antibody increase as “nine-fold higher than 28 days after the main single-dose vaccination.” The significant improvement was seen in clinical trial participants between the ages of 18 and 55, and in those 65 years and older, who received the lower booster dose.
“The Phase 1/2a clinical trial is smaller than Phase 3 designed to demonstrate the vaccine’s efficacy,” the company statement said. Johnson & Johnson is also studying two doses of the vaccine being trialled on 30,000 people in a Phase 3 trial, the results of which have not yet been released.
–
–
–
Mathai Mammen, head of global research for Johnson & Johnson, said the company submitted the results of the study to the US Food and Drug Administration (FDA), US Centers for Infectious Disease Control and Prevention (CDC), European Medicines Agency (EMA) and health authorities. other. The company hopes their vaccine can be used as a booster, eight months or more after the first single-dose vaccination. [mg/ka]
–
– .
